Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy

You may be eligible if

• Histologically confirmed malignant pleural mesothelioma meeting 1 of the following cell types:
• * Epithelial
• * Sarcomatoid
• * Mixed type
• * Histologically documented malignant pleural mesothelioma, epithelial, sarcomatoid or mixed type, not amenable to surgical resection
• * Prior treatment
• Currently receiving first-line treatment with pemetrexed + platinum; patients are to be registered to Cancer and Leukemia Group B (CALGB) 30901 no later than the last day of cycle 4 of first line therapy
• Prior intracavitary cytotoxic or sclerosing therapy (including bleomycin) are acceptable; prior intrapleural cytotoxic chemotherapy will not be considered systemic chemotherapy
• Prior surgical treatment is allowed
• Prior radiation therapy is allowed
• * Non-pregnant and non-nursing; women of child bearing potential and men must agree to use an appropriate method of birth control throughout their participation in this study; appropriate methods of birth control include abstinence, oral contraceptives, implantable hormonal contraceptives (Norplant), or double barrier methods (diaphragm plus condom)
• * RANDOMIZATION ELIGIBILITY CRITERIA
• * Patients with complete response, partial response, or stable disease following 4, 5 or 6 cycles of first-line chemotherapy with pemetrexed AND either cisplatin or carboplatin; a maximum of 6 cycles of chemotherapy may have been given
• * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
• * Granulocytes \>= 1,500/ul
• * Platelet count \>= 100,000/ul
• * Total bilirubin =\< 1.5 x upper limit of normal (ULN)
• * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) =\< 2 x ULN
• * Calculated creatinine clearance \>= 45 ml/min
• Disease not amenable to surgery
• Must be enrolled on imaging protocol CALGB-580903
• Complete response, partial response, or stable disease after completion of 4 courses of first-line chemotherapy comprising pemetrexed disodium AND cisplatin or carboplatin
• * Study therapy will begin within 9 weeks following day 1 of cycle 4 of first-line treatment
• No clinically significant pleural or peritoneal effusions that cannot be adequately managed by drainage before or during pemetrexed disodium
• PATIENT CHARACTERISTICS:
• ECOG performance status of 0-1
• Life expectancy ≥ 12 weeks
• Granulocytes ≥ 1,500/μL
• Platelet count ≥ 100,000/μL
• Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
• AST ≤ 2 times ULN
• Creatinine clearance ≥ 45 mL/min
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No psychiatric illness that would prevent the patient from giving informed consent
• No second malignancy except non-melanoma skin cancer or carcinoma in situ of the cervix unless curatively treated with no evidence of active disease for ≥ 5 years
• No medical conditions that, in the opinion of the treating physician, would make study treatment unreasonably hazardous for the patient including, but not limited to, the following:
• * Ongoing or active infection such as HIV positivity
• * Inability to take oral medications
• * Psychiatric illness/social situations that would limit compliance with study requirements
• PRIOR CONCURRENT THERAPY:
• See Disease Characteristics
• Prior intracavitary cytotoxic or sclerosing therapy (including bleomycin) allowed
• * Prior intrapleural cytotoxic chemotherapy not considered systemic chemotherapy
• Prior surgery allowed
• Prior radiotherapy allowed
• * No concurrent palliative radiotherapy
• No concurrent hormones or other chemotherapeutic agents except for the following:
• * Steroids for adrenal failure
• * Hormones for nondisease-related conditions (e.g., insulin for diabetes)
• * Intermittent use of dexamethasone as an antiemetic or premedication for pemetrexed disodium